Elevated Serum Interferon Levels in Patients With Bell's Palsy

Jönsson, Lars; Alm, Gunnar V.; Thomander, Lars

doi:10.1001/archotol.1989.01860250039022

Cited by 17 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An infectious cause associated with an autoimmune response may be in volved in the disease [1,2], This is in agree ment with the finding of a prolonged immu nological response during the course of the disease [3]. In accordance with an immuno logical dysfunction, elevated serum levels of complement component Clq-and comple ment component C3-containing circulating immune complexes have been reported in the acute stage of Bell's palsy [4,5].…”

Section: Introductionsupporting

confidence: 67%

Bell’s Palsy: An Immune Complex Disease

Larsson

Jönsson

Sjöquist

1990

ORL

View full text Add to dashboard Cite

Serum levels of C4-containing circulating immune complexes in 48 patients with Bell’s palsy were studied by an enzyme-linked immunosorbent assay (ELISA) using chicken antibodies. We have previously reported elevated levels of Clq- and C3-containing immune complexes when compared to the serum of 42 healthy persons. We now found the levels of C4-containing immune complexes in these sera to be slightly decreased, but these patients’ sera had a slightly increased ability to activate and bind C4 to a model immune complex. The results indicate that the fairly low levels of C4-containing immune complexes were not due to a defect in C4 activation but point to a rapid modification of C4 in the immune complex in vivo or low binding of C4 to the immune complexes. This study also shows that it is preferable to use assays that detect Clq- and C3-containing immune complexes when analyzing sera from patients with Bell’s palsy.

show abstract

Section: Introductionsupporting

confidence: 67%

Bell’s Palsy: An Immune Complex Disease

Larsson

Jönsson

Sjöquist

1990

ORL

View full text Add to dashboard Cite

show abstract

“…The circulating IFN-~ is unusual in that it shows an acid lability not typically seen for IFN-~t. Acid labile serum IFN-~ is also seen in a number of different clinical scenarios, including patients with lupus Yee et al, 1989), multiple sclerosis (unpublished results), juvenile arthritis (Arvin and Miller, 1984), Bell's palsy (Jonsson et al, 1989) and some acute viral infections. This serum IFN does not appear to reflect expression of a unique IFN-~ gene or genes whose product is intrinsically acid labile, but rather appears to be conferred by other as yet unidentified serum components (Yee et al, 1989).…”

Section: Ifn Production In Aidsmentioning

confidence: 92%

Human natural interferon-α producing cells

Fitzgerald-Bocarsly

1993

Pharmacology & Therapeutics

198

147

View full text Add to dashboard Cite

Interferons (IFNs) are critical components of the host immune system, serving as antiviral agents, immunomodulators and inhibitors of cell growth. Among peripheral blood mononuclear cells, the primary IFN-alpha-producing cell is a light density, HLA-DR+ cell negative for cell surface markers typical for T cells, B cells, monocytes, natural-killer or progenitor cells and has been tentatively termed the 'natural IFN-producing cell' or NIPC. Although present in very low frequency (approximately 1:1000 among peripheral blood mononuclear cells), the NIPC are very potent, with an individual cell able to produce 1-2 IU of IFN. In this review, the characteristics, phenotype, regulation and relationship of NIPC to human disease are discussed.

show abstract

“…A recent report by Austin et al 3 demonstrated the clinical usefulness of prednisone when compared with placebo in patients with Bell's palsy. However, in the current literature the viral pathogenetic hypothesis is gaining acceptance, suggesting that the herpes simplex virus may play a fundamental role in IFNP 4‐8 . Viral DNA has been recently identified in endoneural fluid and muscle of patients with IFNP, suggesting that herpes simplex virus plays an important role in the etiopathogenesis of IFNP 9,10 .…”

Section: Introductionmentioning

confidence: 99%

Idiopathic Facial Paralysis: A Randomized, Prospective, and Controlled Study Using Single‐Dose Prednisone Versus Acyclovir Three Times Daily

et al. 1998

View full text Add to dashboard Cite

In a prospective, controlled, and randomized study, we compared the outcome of 101 Bell's palsy patients treated with acyclovir (54 patients) or prednisone (47 patients). The acyclovir dosage was 2400 mg (800 mg three times a day) for 10 days, and prednisone was given as a single daily dose of 1 mg/kg of body weight for 10 days and tapered to 0 over the next 6 days. Minimum follow-up was 3 months in all patients. Patients in the prednisone group had better clinical recovery than those treated with acyclovir. Less degree of neural degeneration was observed in the prednisone group compared with acyclovir patients. The incidence of sequelae was the same in both groups. According to these results, in a 10-day treatment cycle acyclovir given 800 mg three times is not as useful as prednisone given 1 mg/kg of body weight once a day in patients with idiopathic facial nerve paralysis.

show abstract

Elevated Serum Interferon Levels in Patients With Bell's Palsy

Cited by 17 publications

References 28 publications

Bell’s Palsy: An Immune Complex Disease

Bell’s Palsy: An Immune Complex Disease

Human natural interferon-α producing cells

Idiopathic Facial Paralysis: A Randomized, Prospective, and Controlled Study Using Single‐Dose Prednisone Versus Acyclovir Three Times Daily

Contact Info

Product

Resources

About